Combination Pill Reduces Risk of Recurrent Brain Hemorrhage

New “Triple Pill” Cuts Recurrent Stroke Risk by Nearly 40% in High-Risk Patients, Study Finds

A once-daily combination pill containing three low-dose blood pressure medications significantly reduces the risk of a second stroke in survivors of brain bleeds, according to a landmark international study published in the New England Journal of Medicine. The findings could transform secondary prevention for one of the most vulnerable patient groups in neurology.

The seven-year clinical trial, led in part by researchers at Radboud University Medical Center in the Netherlands, found that patients taking the so-called “triple pill” were 39% less likely to experience another stroke compared to those given a placebo. The study similarly revealed broader cardiovascular benefits: participants on the medication saw their blood pressure drop by an average of nine points and experienced fewer serious heart and vascular events overall.

A Breakthrough for High-Risk Survivors

Brain bleeds—medically known as hemorrhagic strokes—strike roughly 8,000 to 9,000 people in the Netherlands each year, with similarly devastating numbers reported globally. “About one-third of patients die within a month of the initial bleed,” said Karin Klijn, a professor of neurology at Radboudumc and a leading expert on brain hemorrhages. “Of those who survive, half remain permanently dependent on care. These are some of the most fragile patients in medicine.”

The study, dubbed TRIDENT, is the largest of its kind to examine interventions specifically aimed at preventing recurrent strokes after a brain bleed. Previous research has established high blood pressure as a major risk factor for both hemorrhagic and ischemic strokes—where a blood vessel is blocked by a clot—but effective, well-tolerated treatments for secondary prevention have remained elusive.

Lower Doses, Fewer Side Effects

One of the most promising aspects of the triple pill is its design: by combining three blood pressure-lowering drugs at lower-than-standard doses, the medication appears to minimize side effects although maximizing efficacy. “Patients in the study not only had better outcomes—they also reported fewer adverse effects compared to traditional high-dose regimens,” the researchers noted. This could be particularly critical for long-term adherence, as many stroke survivors struggle with complex medication schedules.

The implications extend beyond stroke prevention. “Uncontrolled high blood pressure is often called the ‘silent killer’ since it can go unnoticed for years,” Klijn explained. “Many people live with elevated blood pressure without obvious symptoms, which makes consistent treatment all the more critical.” The triple pill’s streamlined approach could simplify care for patients who might otherwise skip doses or discontinue treatment due to side effects.

Global Impact and Next Steps

While the study’s results are compelling, experts caution that further research is needed to determine how the triple pill compares to other blood pressure management strategies in real-world settings. Still, the findings offer a glimmer of hope for a patient population that has long faced limited options. “This is a significant step forward in protecting survivors from the devastating consequences of a second stroke,” Klijn said.

For now, the study underscores the importance of aggressive blood pressure control in high-risk individuals. Public health advocates hope the results will encourage more patients and providers to prioritize early intervention, particularly in communities where stroke risk factors like hypertension are prevalent but underdiagnosed.

The full study is available in the latest issue of the New England Journal of Medicine.